130 likes | 551 Views
Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia . Jigna Joshi MD Marian Macsai MD Parag Majmudar MD Vanee Virasch MD A Collaboration between Northwestern and Rush University.
E N D
Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia Jigna Joshi MD Marian Macsai MD Parag Majmudar MD Vanee Virasch MD A Collaboration between Northwestern and Rush University Dr. Macsai is a member of the speakers bureau for Allergan and Alcon. Dr. Majmudar is a consultant for AMO.
Purpose • To compare outcomes of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in patients with high myopia
Methods • A retrospective chart review of consecutive patients implanted with a phakic intraocular lens by one of two experienced surgeons.
Results • Average loss of endothelial cells in the first 12 months was 4.4% in the Verisyse group and 2.5% in the Visian group. • Six (6) patients (8%) in the Verisyse group required enhancements with either PRK or LASIK • Four (4) patients (7.1%) in the Visian group required enhancement with LASIK.
Results • Three eyes required enlargement of Yag peripheral iridotomies within the first post operative month in the Visian group. • Four eyes developed mild peripheral anterior subcapsular opacities that were not visually significant in the Visian group. • No lenses required explantation
Limitations • Small sample size • Endothelial cell counts in the Verisyse group were measured by two different techniques, one pre-op and one post-op, resulting in higher variability in that group • The inherent difference in lens position will result in different complications
Conclusion • Visual outcomes were similar in both intraocular lens groups. • Enhancement rates for residual refractive errors were similar in both intraocular lens groups. • Rate of endothelial cell loss was greater in the Verisyse, while the Visian group had more capsular opacities (visually insignificant).
Conclusion • The Visian ICL and the Verisyse Phakic IOL appear to be safe alternatives for the treatment of high myopia. • Post market approval outcomes are helpful for physicians considering including these techniques in their practice.